期刊文献+

血清CysC检测在胃癌患者的临床应用

下载PDF
导出
摘要 目的探讨胃癌患者血清胱抑素C含量检测的临床意义。方法胃癌患者106例为研究组,健康体检人群96例为对照组。用全自动生化分析仪检测两组人群的血清胱抑素C含量,比较两组间以及胃癌组中转移与未转移患者血清胱抑素C含量的情况。结果胃癌组与健康对照组胱抑素C含量分别为(7.12±2.37)mg/L和(0.86±0.21)mg/L,两组比较差异有统计学意义(t=12.8612,P<0.01),转移与未转移患者比较差异无统计学意义(t=0.4250,P>0.05)。结论胃癌患者血清胱抑素C检测值远远高于正常人群,提示血清胱抑素C检测在胃癌的早期诊断、治疗等方面可能会有很重要的临床意义。
出处 《广州医药》 2010年第6期51-53,共3页 Guangzhou Medical Journal
  • 相关文献

参考文献8

  • 1弓孟春,胡蓉蓉,李雪梅,李学旺.胱抑素C的临床应用进展[J].中华内科杂志,2009,48(10):880-882. 被引量:4
  • 2Tanaka A,Suemaru K,Araki H.A new approach for evaluating renal function and its practical application[J].J Pharmacol Sci,2007,105(1):1-5.
  • 3Hirai K,Yokoyama M,Asano G,et al.Expression of Cathepsin B and Cystatin C in human colorectal cancer[J].Human Pathol,1999,30(6):680-686.
  • 4Salch Y,Sebzda T,Warwas M,et al.Expression of cystatin C in clinical human colorectal cancer tissues[J].J Exp Ther Oncol,2005,5(1):49-53.
  • 5Nishikawa H,Ozaki Y,Nakanishi T,et al.The role of Cathepsin B and Cystatin C in the mechanisms of invasion by ovarian cancer[J].Gynecol Oncol,2004,92(3):881-886.
  • 6康懿,王蕾,高锋.血清半胱氨酸蛋白酶抑制剂C测定在结直肠恶性肿瘤中的价值[J].检验医学,2006,21(6):683-685. 被引量:1
  • 7Mulaomerovie A,Halilbasie A,Cickusie E,et al.Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma[J].Cancer Lett,2007,248(2):192-197.
  • 8Strojan P,Svetic B,Smid I,et al.Serum Cystatin C in patients with head and neck carcinoma[J].Clin Chim Acta,2004,344(1~2):155-161.

二级参考文献37

  • 1Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis, 2008, 51 : 373-384.
  • 2Chen W, Chen W, Wang H, et al. Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant, 2009, 24 : 1205-1212.
  • 3Madero M, Sarnak MJ. Association of eystatin C with adverse outcomes. Curr Opin Nephrol Hypertens, 2009, 18: 258-263.
  • 4Stevens LA, Schimid CH, Greene T. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int, 2009,75:652-660.
  • 5Foley RN, Wang C, Snyder J J, et al. Cystatin C levels in U. S.adults, 1988-1994 versus 1999-2002: NHANES. Clin J Am Soc Nephrol, 2009,4:965-972.
  • 6Kotgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: the third national health and nutrition examination survery ( NHANES III ). Am J Kidney Dis, 2008,51:385-394.
  • 7Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum eystatin C levels in adults in the United States. Am J Med, 2008,121: 341-348.
  • 8Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine : a pooled analysis of 3418 individuals with CKD. Am J Kidney Dis, 2008,51:395-406.
  • 9Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest, 1985,45:97-101.
  • 10Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatine. Kidney Int, 1995,47:312- 318.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部